Summary
Johnson & Johnson (JNJ) filed an 8-K on January 24, 2023, to report its fourth quarter and full-year financial results for the period ended January 1, 2023. The report primarily contains a press release and supplementary financial data, highlighting the company's operational and financial performance. Investors should review these documents for details on sales, earnings, and other key financial metrics that could impact the company's valuation and future outlook.
Key Highlights
- 1JNJ announced its Q4 and full-year 2022 financial results on January 24, 2023, via an 8-K filing.
- 2The filing includes a press release detailing sales and earnings for the period ended January 1, 2023.
- 3Supplementary sales data and condensed consolidated statements of earnings are provided for the fourth quarter and full year.
- 4This 8-K serves as the primary vehicle for investors to access the company's latest reported financial performance.
- 5No other significant events or business updates were reported in this specific 8-K filing.
Frequently Asked Questions
The main purpose of this 8-K filing is to publicly announce and provide detailed financial results for Johnson & Johnson's fourth quarter and full fiscal year ended January 1, 2023. It includes a press release and supplementary financial data.
The specific sales and earnings figures are detailed in the press release (Exhibit 99.1) and the unaudited comparative supplementary sales data and condensed consolidated statements of earnings (Exhibit 99.2) attached to the 8-K filing.
Based on the provided filing details, this 8-K specifically focuses on the reporting of financial results. It does not indicate any announcements of new strategic initiatives or major company changes beyond the financial performance update.